IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Seeds and traits

Evogene raises $74 million in NYSE debut

9:37 AM MST | November 21, 2013 | Rebecca Coons

Shares of Evogene (Rehovot, Israel), a plant genomics firm in which both Monsanto and Bayer hold significant stakes, debuted on the New York Stock Exchange this morning at $14.75/share. The initial public offering raised approximately $74 million. Monsanto, which already held a 8.7% stake in Evogene, paid about $12 million to acquire 813,560 of the 5 million offered shares. Evogene says it has also granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same price per share. According to an F-1 filed in September...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa